|drug3242||Standard protein group Wiki||1.00|
|drug3847||convalescent plasma Wiki||0.45|
|D009748||Nutrition Disorders NIH||0.71|
|D016638||Critical Illness NIH||0.13|
There is one clinical trial.
The investigator will investigate the effect of supplemental enteral protein (1.2 g/kg/day) added to standard formula to achieve high amount of enteral protein (range 2-2.4 g/kg/day) given from ICU day 5 until ICU discharge up to ICU day 90 as compared to no supplemental enteral protein to achieve moderate amount enteral protein (0.8-1.2 g/kg/day), given in conjunction with similar amounts of stepwise caloric administration in the two groups on all-cause 90-day mortality.
Description: Mortality 90 days post randomizationMeasure: 90 day-all cause mortality Time: 90 days
Description: use of vasopressor/inotropic support, invasive mechanical ventilation and/or renal replacement therapyMeasure: Days alive at day 90 without life support Time: 90 days
Description: 90 day survival after randomizationMeasure: Days alive and out of hospital at day 90 Time: 90 days
Description: Any symptoms of bacteremiaMeasure: Bacteremia until 2 days of ICU stay Time: until 2 days post ICU.
Description: anytime during ICU stayMeasure: New or progression of Skin Pressure Ulcers Time: ICU stay
Description: SARC-F screen for sarcopenia and EuroQoLMeasure: Functional assessment at day 90 Time: Day 90
Description: New episode of stage 2 or higher AKI by KDIGO criteria; 2. Pneumonia defined as episodes of newly confirmed pneumonia according to the modified CDC criteria; 3. Grade IV Acute Gastrointestinal injury (AGI)Measure: Safety outcomes during ICU stay Time: ICU stay
Description: Feeding tolerance; Diarrhoea; Refeeding syndromeMeasure: Minor safety outcomes during ICU stay Time: ICU stay
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports